Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BeiGene Ltd ( (HK:6160) ) has shared an update.
BeOne Medicines Ltd. announced the filing of its Form 10-Q for the quarterly period ending June 30, 2025, with the U.S. Securities and Exchange Commission. This regulatory announcement highlights the company’s compliance with reporting requirements, which is crucial for maintaining its listings on major stock exchanges and ensuring transparency for its stakeholders.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
BeOne Medicines Ltd. is a Swiss corporation operating in the pharmaceutical industry. The company is involved in the development and commercialization of innovative medicines, with its securities listed on both The Nasdaq Global Select Market and The Stock Exchange of Hong Kong Limited.
Average Trading Volume: 6,745,224
Technical Sentiment Signal: Buy
Current Market Cap: HK$282B
For an in-depth examination of 6160 stock, go to TipRanks’ Overview page.